APR Applied Pharma Research Introduces SwitzAge®: The First 100% Swiss Made Nutraceutical Product Line, Developed to Empower Adult Vitality
APR Applied Pharma Research s.a. (“APR”), the Swiss, independent developer of science driven, patent protected healthcare products, is proud to announce the reinforcement of its consumer products portfolio with SwitzAge®, an innovative range of nutraceuticals, 100% Swiss made, specifically created to meet adult people well-being needs.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170731005481/en/
SwitzAge®, the first 100% Swiss made Nutraceutical product line by APR (Photo: APR Applied Pharma Research s.a.)
Life expectancy has been globally growing in the last decades thanks to
the overall improvement of life quality standards and the so-called
Generation X is having a transformative impact on society. By 2050, the
number of over 50s worldwide is projected to double to nearly 3.2
billion people. These consumers are transforming what it means to be
older in terms of lifestyle and aim for an overall improvement of their
vitality, thus being more conscious of their diet and combing it with
the consumption of specific food supplements.
Asia-Pacific
countries, in particular, where adult people account for almost 30% of
the population, seem to drive the growth of the global food supplements
market with an expected CAGR of 9.1% in the next five years, thus
generating nearly half of the whole market, estimated around 84 USD
billion, by 2020.
The SwitzAge® project has been specifically designed to match the
increasing demand for high-quality food supplements tailored on adult
people health needs.
SwitzAge® was inspired from a holistic
approach focused on the specific physiological needs of man and lady for
a balanced well-being of body and mind along the ageing natural course.
Each SwitzAge® product is the result of the Swiss high-quality
pharmaceutical research applied to healthy ageing. In particular,
products formulations contain a balanced mix of active ingredients
- vitamins, minerals and functional extracts, accurately selected
and controlled along the production process according to highest Swiss
quality standards. On the other side, SwitzAge® formulations are
compliant with European, Swiss and current Chinese food supplement
regulations, thus ensuring a favourable tolerability profile.
Moreover,
they are lactose, sugar and gluten free and they all come in user-friendly
pharmaceutical forms (mono-dose effervescent powder, chewable
tablets and soft-gel capsules) for an easier administration, whilst
offering the appropriate daily dosage in compliance with European and
Swiss NRV recommendations.
SwitzAge® product line is currently made of 8 food supplements, that provide the right answers for body and mind enhancement, by improving physical energy extent as well as the overall balance in terms of memory, concentration and sleep quality, along with a proper differentiation per gender. Among the others, the range spans solutions for cardiovascular system efficiency and genitourinary well-being, for men, as well as for menopause hormonal swing regulation and skin anti-ageing for ladies.
"We are very proud - said Paolo Galfetti, CEO and Co-Founder of APR - to offer this new business opportunity to potential partners who are ready to exploit the increasing growth of the food supplement market addressed to adult and mature people needs. Seizing the global trend towards healthy ageing, SwitzAge® is the first range of scientific proven solutions which aims at enhancing adult and mature people quality of life, enabling their physical, social and mental well-being.”
About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis.
For press releases and other company information, please visit: www.apr.ch or www.switzage.ch/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170731005481/en/
Contact information
APR:
PAOLO GALFETTI (CEO), Tel: +41 91 695 70 20
paolo.galfetti@apr.ch
www.apr.ch
or
HAVAS
PR MILAN:
Press Office
SARA BERNABOVI, T: +39 02 85457032
sara.bernabovi@havaspr.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo